Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.
Advertisement
Set Alert for Articles By Alex Shimmings

Latest From Alex Shimmings

Roche Makes Case For Its Oral SMA Drug Risdiplam As Filings Beckon

Novartis may be turning up the rhetoric in spinal muscular atrophy as its cutting-edge gene therapy Zolgensma approaches a market currently enjoyed solely by Biogen’s Spinraza, but Roche is upbeat about the potential of its investigational oral product, risdiplam, to weigh in.

Clinical Trials Rare Diseases

Biotech Showcase 2019: Lipid Nanoparticle-Encased TUSC2 Gene Underpins Phase II NSCLC Asset

Julien Pham, President and COO of Genprex, describes to Mike Ward how the company is using a technology platform to wrap the TUSC2 gene in a cholesterol nanoparticle.

Companies Research and Development Strategies

New Products Soar And Old Stand Their Ground As Roche Heads Off Biosimilar Threat

New products helped Roche to 7% sales growth in 2018 but the outlook for 2019 is lower as the biosimilar headwinds start to blow from the US.

Sales & Earnings Companies

Q4 Pharma Earnings Preview: Roche, Celgene, Novo Nordisk, Merck, Gilead

Roche will highlight newer drugs as cancer blockbusters feel biosimilar pressure, while Celgene will talk to investors about its pending acquisition by Bristol. Novo Nordisk has faced concerns about generic and branded competition not to mention price pressures, but its longer-term outlook is sound; Merck's Keytruda tops investors' focus; Gilead looks ahead to new CEO O'Day.

Sales & Earnings Business Strategies

Follow The Money, An Interactive Biotech Financing Map

In 2018, while biotech venture activity spoke mainly with an American accent, China emerged as the world’s third most active cluster, while the UK led the way in Europe.

Commercial Financing

AstraZeneca Rejig Brings Baselga On Board

A reorganization at the top of the UK firm brings with it controversial scientist Jose Baselga.

Companies Appointments
See All
Advertisement
UsernamePublicRestriction

Register